论文部分内容阅读
目的观察血脂康胶囊在老年缺血性脑血管病(ICVD)急性期治疗中的疗效。方法 63例ICVD患者分为试验组(31例,服用血脂康胶囊0.6g,早晚各1次)和对照组(32例,服用普伐他汀20mg,晚餐后顿服);疗程均为10d。治疗结束时比较两组治疗前后血甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及C反应蛋白(CRP),观察临床降脂有效率。结果治疗结束时试验组和对照组的降脂有效率分别为93.55%和81.25%(P>0.05),血脂康降低TG、TC、LDL-C、CRP的作用与普伐他汀相似,均显著低于治疗前(P<0.01),但升高HDL-C效果优于普伐他汀(P<0.05)。结论血脂康胶囊治疗老年急性期ICVD安全有效。
Objective To observe the effect of Xuezhikang in the treatment of acute ischemic cerebrovascular disease (ICVD) in acute phase. Methods Sixty-three ICVD patients were divided into experimental group (31 cases, taking Xuezhikang capsule 0.6g, morning and evening one time) and control group (32 cases, taking pravastatin 20mg, evening meal after dinner). The course of treatment was 10 days. At the end of treatment, triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and C-reactive protein (CRP) , Observe the clinical lipid-lowering efficiency. Results At the end of treatment, the lipid-lowering effective rates of the experimental group and the control group were 93.55% and 81.25%, respectively (P> 0.05). The effects of Xuezhikang on reducing TG, TC, LDL-C and CRP were similar to those of pravastatin, Before treatment (P <0.01), HDL-C was superior to pravastatin (P <0.05). Conclusion Xuezhikang safe and effective treatment of elderly acute ICVD.